APOC3 and type 2 diabetes mellitus: In studies analyzing the effect of Liraglutide on T2DM patients, Rafiullah et al. [36] reported the downregulation of the urinary protein SERPINA1, and Adiels et al. [37] reported decreased secretion of APOC3 with treatment.